Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population
Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population
Reports suggest that the Medicaid population includes a higher percentage of smokers than the
 general population. A high prevalence of smokers in a population is likely to lead to a
 higher burden of chronic obstructive pulmonary disease (COPD). Few studies have evaluated the
 economic burden of COPD in a Medicaid population. The objective of this observational,
 retrospective cohort study is to estimate the economic burden of COPD in subjects with a COPD
 diagnosis who are enrolled in Medicaid and are receiving maintenance treatment covered by
 Medicaid.

 Specifically, the null hypothesis for the primary outcome measure is that no difference is
 observed in all-cause costs between subjects with and without COPD. The test hypothesis is
 that there is a difference in all-cause costs between subjects with and without COPD.

 Secondary outcomes to be evaluated include all-cause resource use and COPD-related costs for
 the COPD cohort.

 The study uses a medical and pharmacy administrative claims database called MarketScan
 Medicaid Database that contains the medical, surgical, and prescription drug experience of
 nearly 7 million Medicaid recipients. This analysis will use data from 8 states.
Inclusion Criteria:

 -  at least 40 years of age at index date

 -  continuously eligible to receive healthcare services through Medicaid in the pre-index
 and follow-up period

 -  enrolled in fee-for-service plans

 -  without a diagnosis code of exclusionary comorbid conditions - cystic fibrosis,
 bronchiectasis, respiratory cancer, pulmonary fibrosis, pneumoconiosis, sarcoidosis,
 pulmonary tuberculosis (including fibrosis due to tuberculosis)

 Exclusion Criteria:

 -  age less than 40 at index dates